Milestone Pharmaceuticals Inc
NASDAQ:MIST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eurobank Ergasias Services and Holdings SA
ATHEX:EUROB
|
GR |
Milestone Pharmaceuticals Inc
Total Current Liabilities
Milestone Pharmaceuticals Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Milestone Pharmaceuticals Inc
NASDAQ:MIST
|
Total Current Liabilities
$10.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Total Current Liabilities
$4.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-2%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Total Current Liabilities
CA$92.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Total Current Liabilities
$48.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
40%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Total Current Liabilities
$65.4m
|
CAGR 3-Years
36%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Total Current Liabilities
CA$152.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
51%
|
|
Milestone Pharmaceuticals Inc
Glance View
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate is etripamil. The etripamil is a novel, potent and short-acting calcium channel blocker that has been designed rapid-onset nasal spray, which is self-administered by patients. The firm is developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF) and rapid ventricular rate, and other cardiovascular indications.
See Also
What is Milestone Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
10.5m
USD
Based on the financial report for Sep 30, 2025, Milestone Pharmaceuticals Inc's Total Current Liabilities amounts to 10.5m USD.
What is Milestone Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
12%
Over the last year, the Total Current Liabilities growth was 100%. The average annual Total Current Liabilities growth rates for Milestone Pharmaceuticals Inc have been 17% over the past three years , 12% over the past five years .
